| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Information Technology Branch [K. D. P.] and Laboratory of Molecular Pharmacology [C. M. L., E. H.], Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20892, and Laboratory of Pharmaceutical Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland 21701 [L. M.]
Data generated in the new National Cancer Institute drug evaluation program, which are based on inhibition of cell growth in 60 human tumor cell lines, were probed with nine known antimitotic agents using the COMPARE algorithm. Cytotoxicity data were available on approximately 7000 compounds at the time of the analysis, and, based on the criteria used, 82 compounds were selected as positive by the computer search. Nine were the probe compounds themselves, and 41 were analogues of known antimitotic agents. Among the remaining 32 compounds there were 19 distinct chemical species. Agents in ten of these groups (containing 20 compounds) were effective inhibitors of in vitro tubulin polymerization and caused the mitotic arrest of cells grown in culture. Two compounds were related natural products binding in the Vinca domain of tubulin, and the others were synthetic agents which interfered with colchicine binding. The remaining 12 agents (one natural product, the remainder synthetic) fell into several groups: two compounds were weak inhibitors of tubulin polymerization, inhibited colchicine binding, and caused mitotic arrest; one compound weakly inhibited tubulin polymerization but did not cause an increase in the number of cells arrested in mitosis; two compounds caused mitotic arrest at micromolar concentrations, but thus far no in vitro interaction with tubulin has been observed; the remainder neither inhibited tubulin polymerization nor caused a rise in the number of cultured cells arrested in mitosis. Tubulin-dependent GTP hydrolysis was stimulated or inhibited by all agents which inhibited tubulin polymerization with the exception of one compound. The analysis of differential cytotoxicity data thus appears to have great promise for the identification of new antimitotic agents with antineoplastic potential.
1 To whom requests for reprints should be addressed, at Building 37, Room 5C25, NIH, Bethesda, MD 20892.
Received 2/ 6/92. Accepted 5/ 6/92.
This article has been cited by other articles:
|
|
 |
|
  A. Jimeno, G. Hallur, A. Chan, X. Zhang, G. Cusatis, F. Chan, P. Shah, R. Chen, E. Hamel, E. Garrett-Mayer, et al. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer Mol. Cancer Ther., May 1, 2007; 6(5): 1509 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Williams, A. W. G. Burgett, A. S. Atkins, X. Wang, P. G. Harran, and S. L. McKnight Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity PNAS, February 13, 2007; 104(7): 2074 - 2079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Skoufias, S. DeBonis, Y. Saoudi, L. Lebeau, I. Crevel, R. Cross, R. H. Wade, D. Hackney, and F. Kozielski S-Trityl-L-cysteine Is a Reversible, Tight Binding Inhibitor of the Human Kinesin Eg5 That Specifically Blocks Mitotic Progression J. Biol. Chem., June 30, 2006; 281(26): 17559 - 17569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. E. Perlman, M. D. Slack, Y. Feng, T. J. Mitchison, L. F. Wu, and S. J. Altschuler Multidimensional Drug Profiling By Automated Microscopy Science, November 12, 2004; 306(5699): 1194 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Mertins, T. G. Myers, S. L. Holbeck, W. Medina-Perez, E. Wang, G. Kohlhagen, Y. Pommier, and S. E. Bates In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity Mol. Cancer Ther., July 1, 2004; 3(7): 849 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. CHAN, S. N. KHAN, I. HARVEY, W. MERRICK, and J. PELLETIER Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles RNA, March 1, 2004; 10(3): 528 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Jansen, C. E. Camalier, C. Stark, and N. H. Colburn Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity Mol. Cancer Ther., February 1, 2004; 3(2): 103 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Chang, C.-Y. Chang, C.-C. Kuo, L.-T. Chen, Y.-S. Wein, and Y.-H. Kuo Salvinal, a Novel Microtubule Inhibitor Isolated from Salvia miltiorrhizae Bunge (Danshen), with Antimitotic Activity in Multidrug-Sensitive and -Resistant Human Tumor Cells Mol. Pharmacol., January 1, 2004; 65(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lila, T. E. Renau, L. Wilson, J. Philips, G. Natsoulis, M. J. Cope, W. J. Watkins, and J. Buysse Molecular Basis for Fungal Selectivity of Novel Antimitotic Compounds Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2273 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Cruz-Monserrate, H. C. Vervoort, R. Bai, D. J. Newman, S. B. Howell, G. Los, J. T. Mullaney, M. D. Williams, G. R. Pettit, W. Fenical, et al. Diazonamide A and a Synthetic Structural Analog: Disruptive Effects on Mitosis and Cellular Microtubules and Analysis of Their Interactions with Tubulin Mol. Pharmacol., June 1, 2003; 63(6): 1273 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. LEONARDI, G. SAVIO, A. LAUDANI, L. BLASI, and B. AGOSTARA New Approaches to Breast Cancer: Oxaliplatin Combined with 5-Fluorouracil and Folinic Acid in Pretreated Advanced Breast Cancer Patients: Preliminary Reports Ann. N.Y. Acad. Sci., June 1, 2002; 963(1): 91 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. H. Hua, D. Genini, R. Gussio, R. Tawatao, H. Shih, T. J. Kipps, D. A. Carson, and L. M. Leoni Biochemical Genetic Analysis of Indanocine Resistance in Human Leukemia Cancer Res., October 1, 2001; 61(19): 7248 - 7254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roberge, B. Cinel, H. J. Anderson, L. Lim, X. Jiang, L. Xu, C. M. Bigg, M. T. Kelly, and R. J. Andersen Cell-based Screen for Antimitotic Agents and Identification of Analogues of Rhizoxin, Eleutherobin, and Paclitaxel in Natural Extracts Cancer Res., September 1, 2000; 60(18): 5052 - 5058. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. M. Leoni, E. Hamel, D. Genini, H. Shih, C. J. Carrera, H. B. Cottam, and D. A. Carson Indanocine, a Microtubule-Binding Indanone and a Selective Inducer of Apoptosis in Multidrug-Resistant Cancer Cells J Natl Cancer Inst, February 2, 2000; 92(3): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Nieves-Neira, M. I. Rivera, G. Kohlhagen, M. L. Hursey, P. Pourquier, E. A. Sausville, and Y. Pommier DNA Protein Cross-Links Produced by NSC 652287, a Novel Thiophene Derivative Active Against Human Renal Cancer Cells Mol. Pharmacol., September 1, 1999; 56(3): 478 - 484. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. Zaharevitz, R. Gussio, M. Leost, A. M. Senderowicz, T. Lahusen, C. Kunick, L. Meijer, and E. A. Sausville Discovery and Initial Characterization of the Paullones, a Novel Class of Small-Molecule Inhibitors of Cyclin-dependent Kinases Cancer Res., June 1, 1999; 59(11): 2566 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alvarez, R. Robey, V. Sandor, K. Nishiyama, Y. Matsumoto, K. Paull, S. Bates, and T. Fojo Using the National Cancer Institute Anticancer Drug Screen to Assess the Effect of MRP Expression on Drug Sensitivity Profiles Mol. Pharmacol., November 1, 1998; 54(5): 802 - 814. [Abstract] [Full Text]
|
|
|
|
|
|
G. Kohlhagen, K. D. Paull, M. Cushman, P. Nagafuji, and Y. Pommier Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison Mol. Pharmacol., July 1, 1998; 54(1): 50 - 58. [Abstract] [Full Text]
|
|
|
|
|
|
S. Scala, N. Akhmed, U. S. Rao, K. Paull, L.-B. Lan, B. Dickstein, J.-S. Lee, G. H. Elgemeie, W. D. Stein, and S. E. Bates P-Glycoprotein Substrates and Antagonists Cluster into Two Distinct Groups Mol. Pharmacol., June 1, 1997; 51(6): 1024 - 1033. [Abstract] [Full Text]
|
|
|
|
|
|
J. Weinstein, K. Kohn, M. Grever, V. Viswanadhan, L. Rubinstein, A. Monks, D. Scudiero, L Welch, A. Koutsoukos, A. Chiausa, et al. Neural computing in cancer drug development: predicting mechanism of action Science, October 16, 1992; 258(5081): 447 - 451. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
